Salmon Calcitonin for Injection

Calcitonin is one of the hormones that regulates calcium metabolism and inhibits the parathyroid gland. It can significantly reduce bone calcium loss in high-turnover bone diseases, such as osteoporosis, deforming bone disease (Paget's disease), painful neuropathy (Sudeck's disease) and malignant osteolysis. Its effect on the trunk bones of postmenopausal osteoporosis is more significant than that on the limbs and on high-turnover bone diseases than low-turnover bone diseases. It can inhibit osteoclast activity and stimulate osteoblast formation and activity. Calcitonin can also inhibit osteolysis, thereby reducing pathologically elevated blood calcium concentrations and increasing urinary calcium, phosphorus and blood sodium excretion by reducing tubular reabsorption; however, serum calcium will not fall below the normal range. Calcitonin inhibits the secretory activity of the stomach and pancreas, but does not affect gastrointestinal motility. Clinical trials have shown that this product has analgesic effects on patients with certain painful bone diseases. All calcitonins are structurally similar, with a single chain and 32 amino acids in different arrangements. The order of amino acid arrangement depends on the species. Salmon calcitonin has a high affinity for its receptor binding site (its receptor binding site has also been proven in certain areas of the central nervous system), has very good clinical effects and lasts longer than synthetic mammalian (including human) calcitonin. Pharmacokinetics: According to literature reports: After intramuscular or subcutaneous injection of calcitonin, its absolute bioavailability is about 70%, reaching the peak plasma concentration within one hour, and the elimination half-life is 70 to 90 minutes. 95% of the drug is excreted through the kidneys, of which 2% is excreted as the prototype and 30% to 40% is protein-bound. Its apparent distribution volume is 0.15 to 0.3L/kg.

Salmon calcitonin.

This product is white freeze-dried block or powder.

1. Early and late postmenopausal osteoporosis and senile osteoporosis where conventional estrogen combined with calcium preparations is contraindicated or cannot be used. 2. Hypercalcemia secondary to bone metastasis of breast cancer, lung cancer or kidney cancer, myeloma and other malignant tumors. 3. Osteitis deformans. 4. Hyperparathyroidism, lack of activity or vitamin D poisoning (including acute or chronic poisoning). 5. Painful neurodystrophy or Sudeck's disease.

When using, add 1ml of sterile water for injection to dissolve each vial. Subcutaneous or intramuscular injection, medication should be used under the guidance of a doctor. Osteoporosis: once a day, depending on the severity of the disease, 10-20 μg each time or 20 μg every other day. To prevent progressive bone loss, calcium and vitamin D should be taken in appropriate amounts according to individual needs. Hypercalcemia: 1-2 μg per kilogram of body weight per day, once or twice subcutaneously or intramuscularly. Treatment should be adjusted according to the patient's clinical and biochemical response. If the injection dose exceeds 2ml, multiple injections should be taken. Osteitis deformans: 20 μg daily or every other day. Painful neurodystrophy: Early diagnosis is important, and once confirmed, calcitonin treatment should be used as soon as possible. 20 μg subcutaneously or intramuscularly daily for 2-4 weeks; then 20 μg three times a week for more than 6 weeks; this depends on the patient's response.

1. Nausea, vomiting, dizziness, mild facial flushing with fever may occur. These adverse reactions are dose-related and are more common with intravenous injection than with intramuscular or subcutaneous injection. 2. Rare polyuria and chills have been reported. In rare cases, administration of this product can lead to allergic reactions, including local reactions at the injection site or systemic skin reactions. Individual allergic reactions have been reported to cause tachycardia, hypotension, and collapse.

1. Patients who are allergic to calcitonin are prohibited from using this product. 2. Pregnant and lactating women are prohibited from using this product.

1. Antacids and cathartics often contain calcium or other metal ions such as magnesium and iron, which may affect the absorption of this drug. 2. Combination with aminoglycosides may induce hypocalcemia.

Protect from light and store at 2-8℃.

100IU

Qingdao Guoda Biopharmaceutical Co., Ltd.

• Founded in:

  1999-01-20

• Address:

  Qianwangang Road, Qingdao Economic and Technological Development Zone

• Tax NO.:

  91370200713716738U

• Registered Funds:

  107.9964 million yuan

• Website:

  Log in to view

• Email:

  Log in to view